The future of Four Seasons Health Care, one of Britain's biggest nursing home companies, has been thrown into doubt following the collapse of merger talks with the Priory Group.

Intercytex, a leading developer of regenerative medicine products, said on December 22, it will issue seven million new shares to buy stem cell specialist Axordia.

SkyePharma plc said talks about the U.S. commercialisation of its asthma treatment Certihaler have ended after advisors to the Food and Drug Administration (FDA) questioned the benefits of the drug.

Tibotec Pharmaceuticals is currently recruiting across Europe for two major phase III efficacy trials of its HIV drug TMC278.

H Lundbeck AS is continuing development of nalmefene for the treatment of alcoholism, initiating three phase III clinical trials with the compound.

Switzerland’s Novartis said on Friday that first Phase III results for its FTY720 drug showed superior efficacy to a current standard of care for patients with relapsing multiple sclerosis.

AstraZeneca announced today, December 11, that it has returned worldwide rights to Infinity Pharmaceuticals for the development and commercialisation of IPI-504 and IPI-493.

Sanofi-Aventis SA said Wednesday, December 10, its finance head had stepped down from the company, barely two weeks after former GlaxoSmithKline executive Chris Viehbacher took over as CEO.

Southern Cross Healthcare Group plc swung to a full-year pretax loss after a “difficult year”.

Swiss drugmaker Roche Holding AG is still committed to its $43.7 billion bid to buy out U.S. biotechnology group Genentech Inc, its Chief Executive has said.